Cesca Executive Management Meets With Key Congressional Leaders On The Regenerative Medicine Promotion Act Of 2014
4/30/2014 9:35:00 AM
RANCHO CORDOVA, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that its CEO, Matthew Plavan and President, Ken Harris held several meetings yesterday with key members and members' senior staff of the U.S. Congress and U.S. Senate in Washington D.C. Cesca management discussed the importance of passing Senate Bill S.2126 and House Bill H.R. 4494 - The Regenerative Medicine Promotion Act of 2014, as well as the potential clinical benefit and cost savings impact Cesca's SurgWerks-CLI product, a mid-to-late stage clinical trial treatment for non-operable critical limb ischemia, will have on the U.S. healthcare system. Mr. Plavan and Mr. Harris focused on the delegation from Texas where the incidence of critical limb ischemia is among the highest in the country. They were honored with meetings in the following offices:
Help employers find you! Check out all the jobs and post your resume.
comments powered by